• Knight Therapeutics’ third-quarter 2026 net loss narrowed 29% year over year to CAD 2.68 million.
• Revenues rose 13% year over year to CAD 137.69 million, driven primarily by promoted-product growth and stronger Latin American currencies.
• Operating cash inflow more than doubled year over year to CAD 26.09 million.
• An exclusive distribution agreement with Kyowa Kirin International added Poteligeo rights in Brazil, Mexico, Colombia and Argentina.
• FY26 revenues guidance rose to CAD 560 million–CAD 570 million, supported by stronger promoted-product performance and better-than-expected Latin American currencies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050630PRIMZONECNPR____9870776) on November 05, 2026, and is solely responsible for the information contained therein.